Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
In subjects with PPF, nintedanib reduced circulating CA-125 and, to a lesser extent, other markers of epithelial dysfunction.
Authors
- Carina Ittrich
- Claudia Diefenbach
- Martin Kolb
- Shervin Assassi (ORCID: https://orcid.org/0000-0002-8059-9978)
- Gísli Jenkins (ORCID: https://orcid.org/0000-0002-7929-2119)
- Francesco Bonella (ORCID: https://orcid.org/0000-0001-7579-9767)
- Toby M. Maher (ORCID: https://orcid.org/0000-0001-7192-9149)
- Klaus Röhr
Institutions
- University of Southern California (US)
- Boehringer Ingelheim (Germany) (DE)
- Ruhrlandklinik (DE)
- Imperial College London (GB)
- St. Joseph’s Healthcare Hamilton (CA)
- McMaster University (CA)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1183/23120541.00158-2025
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00